Boriskina L N, Khzardzhan Yu Yu, Zotov A S, Balalin A S, Kuznetsova N V
Volgograd branch of S. Fyodorov Eye Microsurgery Federal State Institution, 80 Zemlyachki St., Volgograd, Russian Federation, 400138.
Vestn Oftalmol. 2018;134(5):92-98. doi: 10.17116/oftalma201813405192.
To study the effectiveness of intravitreal aflibercept in high pigment epithelium detachment (PED) in eyes with age-related macular degeneration (AMD).
This study included 16 eyes of 16 patients (10 female and 6 male) aged 52 to 82 years (mean age 68.56±2.31 years). Examination of patients included determination of best-corrected visual acuity (BCVA), biomicroscopy with Goldmann lens, photographic recording of the ocular fundus, optical coherence tomography (OCT) and OCT-angiography. Results of the treatment were evaluated 1 month after the third injection of aflibercept. Among the analyzed parameters were: BCVA, maximum PED height, resorption of perifocal neuroepithelium detachment (NED), expressiveness of hyperreflective content of PED.
One months into the treatment, after the third injection, mean BCVA improved by 0.09 to 0.36±0.04, height of PED decreased in average by 225.3±44.6 µm to 326.88±25.13 µm. Complete resolution of PED was not achieved in any of the cases. Resulting mean height of perifocal PED was 61.25±12.87 µm. Full resorption of PED was achieved in 4 eyes. Expressiveness of hyperreflective content of PED higher than 50% was observed in 13 eyes (81.25%).
The results of intravitreal aflibercept in AMD patients with high PED have proved its effectiveness in reducing maximum PED height, improving resorption of perifocal NED and BCVA. Optically 'empty' PEDs had higher sensitivity to intravitreal aflibercept than hyperreflective PEDs. Statistically significant dependence of BCVA on the height and content of PED was absent.
研究玻璃体内注射阿柏西普治疗年龄相关性黄斑变性(AMD)患者高色素上皮脱离(PED)的有效性。
本研究纳入了16例患者的16只眼(10例女性,6例男性),年龄在52至82岁之间(平均年龄68.56±2.31岁)。对患者的检查包括最佳矫正视力(BCVA)测定、使用戈德曼接触镜进行生物显微镜检查、眼底照相记录、光学相干断层扫描(OCT)和OCT血管造影。在第三次注射阿柏西普1个月后评估治疗结果。分析的参数包括:BCVA、最大PED高度、黄斑周围神经上皮脱离(NED)的吸收情况、PED高反射成分的表现。
治疗1个月后,第三次注射后,平均BCVA提高了0.09至0.36±0.04,PED高度平均下降了225.3±44.6 µm至326.88±25.13 µm。所有病例均未实现PED的完全消退。黄斑周围PED的最终平均高度为61.25±12.87 µm。4只眼实现了PED的完全吸收。13只眼(81.25%)观察到PED高反射成分的表现高于50%。
玻璃体内注射阿柏西普治疗高PED的AMD患者的结果证明了其在降低最大PED高度、改善黄斑周围NED的吸收和BCVA方面的有效性。光学上“空的”PED对玻璃体内注射阿柏西普的敏感性高于高反射性PED。BCVA与PED的高度和成分之间不存在统计学上的显著相关性。